<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04445129</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-994-0001</org_study_id>
    <secondary_id>U1111-1251-7993</secondary_id>
    <nct_id>NCT04445129</nct_id>
  </id_info>
  <brief_title>Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants</brief_title>
  <official_title>A Study to Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using a Portable Electroencephalogram Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether portable devices can provide measurements
      at home similar to those taken in the clinic, in particular in participant with NT1, and to
      investigate night-to-night changes in sleep patterns using these devices at home. This study
      may enable future at-home studies and ultimately lead to a decreased burden on the people who
      need these measurements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-drug study including participants with NT1 and healthy participants using
      devices designed for at-home assessments. The study will assess whether a portable EEG device
      provides an EEG signal comparable to gold-standard inpatient nPSG. The frequency and
      characteristics of wake and sleep patterns and transitions over multiple nights will also be
      characterized. Participants with NT1 who will complete the study TAK-994-1501 (NCT04096560)
      will be eligible to enter the current study following the appropriate washout period (60
      days).

      The study will enroll approximately 36 participants (18 participants with NT1 and 18 healthy
      participants). Participants will be enrolled in the 2 groups:

        -  NT1 Participants

        -  Healthy Participants

      This multi-center trial will be conducted in the United States. The overall time to
      participate in this study is approximately 8 days. The follow-up visit will occur on Day 10
      and during this debrief, participants will answer a questionnaire on user experience (device
      comfort) for the wearable devices.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">February 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep State Scoring From nPSG and Portable EEG Device</measure>
    <time_frame>up to 2 Nights</time_frame>
    <description>The concordance between EEG signals obtained from the portable EEG device with gold-standard nPSG over 2 inpatient night stays will be assessed using data obtained during the inpatient setting from nPSG and a portable EEG device. Scoring of sleep stages occur in 30-seconds epoch based on American Academy of Sleep Medicine (AASM) scoring rules. The output from the nPSG and the portable EEG device will be hand scored for each participant, with the rater assigning 1 of 6 sleep/wake stages to each 30 second epoch 3 stages of non-REM (NREM) sleep (N1, N2, N3), rapid eye movement (REM), wakefulness (W), and uncategorized. The nPSG is a standardized procedure used to assess various sleep parameters, including sleep latency and sleep architecture. nPSG will be used to as the gold-standard comparator to the portable EEG device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage Shift Index (SSI) as Measured by Standard nPSG and EEG Device on Night 2</measure>
    <time_frame>Night 2</time_frame>
    <description>SSI will be measured by standard nPSG and portable EEG device on Night 2 in the clinic as determined by a certified sleep specialist. SSI will be calculated as the number of transitions between any wake or sleep stage divided by hours of total sleep time. The summary of the frequency of different stages of sleep transitions can be represented by SSI, which can be used to differentiate healthy participant from those with sleep pathology. The correlation between the SSI as measured by the portable EEG device and by the nPSG will be analyzed for participants with NT1 and healthy controls. The nPSG is a standardized procedure used to assess various sleep parameters, including sleep latency and sleep architecture. nPSG will be used as the gold-standard comparator to the portable EEG device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SSI as Measured by Standard nPSG and EEG Device During the Period at Home</measure>
    <time_frame>Nights 3-7</time_frame>
    <description>SSI will be measured by portable EEG device on nights 3-7 at home as determined by a certified sleep specialist. SSI will be calculated as the number of transitions between any wake or sleep stage divided by hours of total sleep time. The summary of the frequency of different stages of sleep transitions can be represented by SSI, which can be used to differentiate healthy participant from those with sleep pathology. The SSI will be analyzed using the intrasubject correlation (intraclass correlation across different nights) in participants with NT1 and healthy participants. The nPSG is a standardized procedure used to assess various sleep parameters, including sleep latency and sleep architecture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Microsleeps and State Transitions During the Maintenance of Wakefulness Tests (MWTs)</measure>
    <time_frame>Day 2</time_frame>
    <description>Micro sleeps are defined as the appearance of any stage of sleep arising out of wakefulness lasting from 3 seconds to less than (&lt;) 15 seconds. Micro sleeps will be assessed on the signals obtained from the portable EEG device. State transition refers to the switch between wake and sleep. MWT is a validated, objective measure used to measure excessive daytime somnolence (EDS) in clinical studies. MWT evaluates a person's ability to remain awake under soporific conditions for a defined period. Wakefulness will be measured indirectly by time to fall asleep using MWT. Four 40-minute (1 session) MWT assessments will be administered. Sleep onset is defined as the first epoch of greater than 15 seconds of cumulative sleep in a 30-second epoch. Trials are ended after 40 minutes if no sleep occurs/after unequivocal sleep, defined as 3 consecutive epochs of stage 1 sleep or 1 epoch of any other stage of sleep. If no sleep has been observed, then the latency is defined as 40 minutes.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Narcolepsy Type 1</condition>
  <arm_group>
    <arm_group_label>Narcolepsy Type 1 Participants</arm_group_label>
    <description>Participants with NT1 on stable wake-promoting medications and no-sleep promoting medications will be fitted with the portable electrocardiogram (ECG) device combined with wrist accelerometry and undergo a 2-night gold-standard nPSG combined with the portable EEG device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Participants</arm_group_label>
    <description>Participants who are healthy sex- and age (plus or minus 5 years)-matched controls will be fitted with the portable ECG device combined with wrist accelerometry and undergo a 2-night gold-standard nPSG combined with the portable EEG device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portable EEG Device</intervention_name>
    <description>Portable EEG device is lightweight and designed for nighttime wear.</description>
    <arm_group_label>Healthy Participants</arm_group_label>
    <arm_group_label>Narcolepsy Type 1 Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portable ECG Device</intervention_name>
    <description>Portable ECG device is waterproof and will be adhered to the chest of the participant.</description>
    <arm_group_label>Healthy Participants</arm_group_label>
    <arm_group_label>Narcolepsy Type 1 Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accelerometry</intervention_name>
    <description>Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.</description>
    <arm_group_label>Healthy Participants</arm_group_label>
    <arm_group_label>Narcolepsy Type 1 Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Participants, who maintain a consistent sleep-wake cycle and participants with NT1.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has access to at-home Wi-Fi and can add an internet-ready device with assistance.

          2. Body mass index (BMI) between greater than equal to (&gt;=) 18.0 and less than or equal
             to (&lt;=) 35.0 kilogram per square meter (kg/m^2) at the screening visit.

          3. Must have regular sleep-wake habits (example, routinely spending 6.5 to 8.5 hours
             sleeping nightly, not oversleeping by more than 2 hours on weekends, that is, total
             sleep not more than approximately 10.5 hours) as determined by investigator interviews
             and confirmed in accelerometry/actigraphy records obtained between screening and first
             visit (measured using a minimum of 10 day/night consecutive periods) and who regularly
             fall asleep between 9:30 PM and 12:00 AM (healthy participants only).

          4. Must not require use of sleep aids or must be willing to discontinue use of sleep aids
             for the duration of the study.

          5. Has completed the TAK-994-1501 study, the participant is eligible to enter the current
             study following the appropriate washout period (60 days).

        Participants With NT1 Only:

          1. With NT1 who is drug-na√Øve may also be enrolled.

          2. With NT1 must present with subjective sleep complaint.

          3. With NT1 must have a diagnosis of NT1, as defined by the International Classification
             of Sleep Disorders, 3rd edition (ICSD-3) criteria.

        Exclusion Criteria:

          1. Has a current diagnosis of cancer except for squamous or basal cell skin cancer.

          2. Has a nicotine or marijuana dependence that is likely to have an effect on sleep
             (example, a participant who routinely awakens at night to smoke) and/or an
             unwillingness to discontinue all smoking and nicotine use during the confinement
             portions of the study.

          3. Cannot maintain stable sleep environment at home, for example, due to young children
             not yet sleeping through the night or partners with disrupted sleep (example, shift
             workers).

          4. Undergoing current treatment for hepatitis B with interferon.

          5. Has a risk of suicide according to endorsement of Item 4 or 5 of the screening visit
             Columbia Suicide Severity Rating Scale (C-SSRS) or has made a suicide attempt in the
             previous 6 months.

          6. Has medical condition, such as past or current epilepsy, seizure, head injury/trauma,
             medically significant unstable cardiovascular, pulmonary, hepatic, renal, or
             gastrointestinal disease, that interferes with a normal sleep pattern or would
             preclude enrollment in the view of the investigator.

          7. Has a lifetime history of major psychiatric disorder, such as bipolar disorder or
             schizophrenia.

          8. As of the screening visit and throughout the study, the participant should not be a
             chronic caffeine user, as defined by an excessive (greater than [&gt;] 600 milligram
             [mg]/day) caffeine intake per day.

          9. Has a medical disorder (other than narcolepsy), associated with excessive daytime
             sleepiness. This includes clinically significant obstructive sleep apnea or restless
             legs syndrome that has a significant impact on daytime sleepiness, confirmed by past
             PSG data (example, apnea hypopnea index &gt;10, periodic limb movement disorder index in
             sleep &gt;15) or a periodic limb movement disorder arousal index of &gt;10, or as evaluated
             on interview at the screening visit. Because nPSG data is obtained on Night 1,
             participants may be removed from study if symptoms are observed. Participants removed
             under this criterion will be replaced.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medicalinformation@tpna.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Delta Waves Sleep Disorders and Research Center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Francis Medical Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sleep Wake Disorders Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Trial and Consulting Services</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep Medicine Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bogan Sleep Consultants, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

